Hexham

This research aims to evaluate the long-term safety and explore the efficacy of astegolimab in adults aged 40 to 90 years with chronic obstructive pulmonary disease COPD. It focuses on participants who have completed a 52-week placebo-controlled treatment period in previous studies GB43311 or GB44332. The study is a phase 3, open-label extension to gather extended safety information on this drug in COPD patients. Participants from the parent studies who qualify will receive subcutaneous injections of astegolimab every two weeks throughout the study until it ends. This open-label extension allows all participants to receive the active drug without placebo comparison. The study continues treatment beyond the initial 52-week period to monitor long-term effects. During the study, participants will be monitored for adverse events up to 12 weeks after their last dose of astegolimab. Researchers will collect safety data to understand the incidence of any side effects. The study involves regular assessments and follow-ups to ensure participant well-being, with the total duration lasting until July 2034.

Researchers are studying the safety and effectiveness of a single dose of NTLA-2001 compared to placebo in adults with transthyretin amyloidosis with cardiomyopathy ATTR-CM and a history of heart failure. This multinational, phase 3 trial involves about 1200 participants and aims to better understand how this treatment impacts heart-related events and survival over time. Participants will be randomly assigned to receive either one intravenous infusion of NTLA-2001 or a placebo infusion of normal saline. The study is double-blind, meaning neither the participants nor the researchers know who receives which infusion. The main treatment phase will last at least 18 months and could extend up to about 5 years depending on cardiovascular event rates. During the study, participants will be monitored for cardiovascular deaths and events as primary outcomes. Secondary measures include changes in blood levels of transthyretin protein and heart failure symptoms assessed at baseline and month 18. Participants will undergo regular medical evaluations, blood tests, and questionnaires to assess their heart function and overall health. Safety will be continuously monitored throughout the trial period.